Review findings

Peptide Protocol Wiki March 7, 2026 BPC-157 TB-500 AOD-9604 + 11 more Guide 14 min read Best Peptides for Menopause Symptoms: 2026 Research Guide Research guide covering peptides studied for menopause symptoms including hot flashes, bone loss, cognitive changes, skin aging, sleep disruption, and hormonal regulation.

immunosuppressed states, Ta1 upregulates pro-inflammatory and Th1-associated cytokines (IL-2, IL-12, IFN-gamma, IFN-alpha).

Do not use if the reconstituted solution appears discolored or contains particulate matter. ⚗️ Suggested Bloodwork ( 6 tests) CBC with differential When: Baseline Why: Baseline immune cell counts Lymphocyte subset panel (CD4, CD8, NK cells) When: Baseline Why: Ta1 targets T-cell and NK cell function Hepatitis B panel (HBV DNA, HBeAg, HBsAg) When: Baseline Why: Required for hepatitis B indication; baseline viral status CMP with liver enzymes When: Baseline Why: Liver function baseline Immunoglobulin levels When: Baseline Why:

A meta-analysis of 5 randomized controlled trials including 653 patients with chronic HBV found that Ta1 monotherapy was associated with significantly higher rates of virological response (relative risk 1.56, 95% CI 1.13-2.14) and biochemical response compared to no treatment.

Peptide Protocol Wiki February 17, 2026 Semaglutide Tirzepatide BPC-157 + 1 more You Might Also Like Related content you may find interesting Peptide Immune LL-37 Peptide Immune Thymalin Peptide Immune Glutathione Peptide Immune KPV Table of Contents What is Thymosin Alpha-1?

A controlled trial in HCV genotype 1 patients reported sustained virological response rates of 44% in the Ta1 combination arm versus 24% with standard-of-care therapy alone.

es (56% vs 36%) and enhanced 1-year survival in the Ta1 combination group.

These findings have generated interest in Ta1 as an immunorestorative agent in critical care, particularly during the immunosuppressive phase of sepsis where opportunistic infections contribute to late mortality.

Mechanism Specificity # Although TLR9 and TLR2 have been identified as important signaling targets, the precise molecular receptor or binding partner through which Ta1 initiates its primary signal has not been definitively established.

Ta1 monotherapy demonstrated significantly higher virological response rates (RR 1.56, 95% CI 1.13-2.14) at 12 months post-treatment.

Restore access No thanks, continue reading Related Reading Peptide KPV anti-inflammatory tripeptide Peptide BPC-157 body protection compound Peptide Glutathione peptide How Thymosin Alpha-1 works at the cellular level Overview of Thymosin Alpha-1 benefits and applications Scientific Details Molecular Formula C129H215N33O55 Molecular Weight 3108.3 Da CAS Number 62304-98-7 Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn What is Thymosin Alpha-1? # Thymosin Alpha-1 (Ta1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein and colleagues in the 1970s.

For antimicrobial peptide research and innate immunity studies, LL-37 provides irreplaceable mechanistic value. → Thymosin Alpha-1 vs Thymalin Thymosin Alpha-1 has substantially stronger evidence by international standards, with regulatory approval in 35+ countries, well-characterized molecular identity, and a defined mechanism of action.

sponse significantly higher with Ta1 versus control (RR 1.56) Response rates continued to improve for 6-12 months after treatment cessation Safety profile equivalent to placebo with no treatment discontinuations due to adverse events Effects of Thymosin Alpha-1 on Immune Function in Patients with Severe Sepsis (ETASS Study) , published in Critical Care (Wu J et al., 2013;

Restore access No thanks, continue reading Related Reading Peptide KPV anti-inflammatory tripeptide Peptide BPC-157 body protection compound Peptide Glutathione peptide How Thymosin Alpha-1 works at the cellular level Overview of Thymosin Alpha-1 benefits and applications Scientific Details Molecular Formula C129H215N33O55 Molecular Weight 3108.3 Da CAS Number 62304-98-7 Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn What is Thymosin Alpha-1? # Thymosin Alpha-1 (Ta1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein and colleagues in the 1970s.

The combination arm received Ta1 1.6 mg SC twice weekly for 26 weeks plus IFN-alpha 9 MU three times weekly for 24 weeks.

Restore access No thanks, continue reading Related Reading Peptide KPV anti-inflammatory tripeptide Peptide BPC-157 body protection compound Peptide Glutathione peptide How Thymosin Alpha-1 works at the cellular level Overview of Thymosin Alpha-1 benefits and applications Scientific Details Molecular Formula C129H215N33O55 Molecular Weight 3108.3 Da CAS Number 62304-98-7 Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn What is Thymosin Alpha-1? # Thymosin Alpha-1 (Ta1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein and colleagues in the 1970s.

ression Related Reading # Thymosin Alpha-1 research studies and evidence Thymosin Alpha-1 dosing protocols Thymosin Alpha-1 side effects profile Glutathione research guide LL-37 research guide Stay current on Thymosin Alpha-1 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 14 min read Peptide Stacking Guide 2026: Best Combinations by Goal The definitive 2026 guide to peptide stacking organized by go

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 14 min read Peptide Stacking Guide 2026: Best Combinations by Goal The definitive 2026 guide to peptide stacking organized by go

Peptide Protocol Wiki February 17, 2026 Semaglutide Tirzepatide BPC-157 + 1 more You Might Also Like Related content you may find interesting Peptide Immune LL-37 Peptide Immune Thymalin Peptide Immune Glutathione Peptide Immune KPV Table of Contents What is Thymosin Alpha-1?

Peptide Protocol Wiki February 26, 2026 Kisspeptin PT-141 (Bremelanotide) GHK-Cu + 8 more News 8 min read Compounding Pharmacy Peptide Access: 2026 Regulatory Changes An overview of the 2026 regulatory landscape for compounded peptides, covering FDA enforcement actions, the impact on semaglutide and tirzepatide compounding, 503A and 503B pharmacy rules, and what patients and providers need to know about peptide access.

Peptide Protocol Wiki March 7, 2026 BPC-157 TB-500 AOD-9604 + 11 more Guide 14 min read Best Peptides for Menopause Symptoms: 2026 Research Guide Research guide covering peptides studied for menopause symptoms including hot flashes, bone loss, cognitive changes, skin aging, sleep disruption, and hormonal regulation.

In its native form, Ta1 is N-terminally acetylated and has a molecular weight of approximately 3108 daltons.

Immune Support Healing & Tissue Repair LL-37 LL-37: Human cathelicidin antimicrobial peptide guide.

Toll-Like Receptor Signaling # A primary mechanism of Ta1 involves activation of Toll-like receptors (TLRs), particularly TLR9 and TLR2, on dendritic cells and other innate immune cells.

cells (pDCs), Ta1 upregulates the expression of co-stimulatory molecules CD80, CD86, and MHC class II, enhancing their capacity to present antigens to T cells.

In randomized controlled trials, Ta1 monotherapy (1.6 mg subcutaneous twice weekly for 6 months) demonstrated sustained virological re

dose: 1.6 mg · route: subcutaneous · duration: for 6 months · frequency: twice weekly

A multicenter randomized controlled trial in China (ETASS study) enrolling 361 patients with severe sepsis found that Ta1 (1.6 mg subcutaneous daily for 7 days) improved 28-day all-cause mortality (26.0% vs 35.0% in controls, p=0.062), with a significant reduction in the HLA-DR-negative monocyte population, indicating reversal of

dose: 1.6 mg · route: subcutaneous · duration: for 7 days · frequency: daily

Patients received TACE with or without concurrent Ta1 1.6 mg SC daily for 5 days per TACE cycle followed by twice-weekly maintenance.

dose: 1.6 mg · cycle: cycle · duration: for 5 days · frequency: daily

It is administered as a subcutaneous injection, typically at doses of 1.6 mg twice weekly.

dose: 1.6 mg · route: subcutaneous · frequency: twice weekly

The combination arm received Ta1 1.6 mg SC twice weekly for 26 weeks plus IFN-alpha 9 MU three times weekly for 24 weeks.

dose: 1.6 mg · duration: for 26 weeks · frequency: twice weekly

Patients received thymalfasin 1.6 mg SC daily for 7 days or standard care alone.

dose: 1.6 mg · duration: for 7 days · frequency: daily

Key Research Findings # Meta-analysis of Thymosin Alpha-1 for Treatment of Patients with Chronic Hepatitis B , published in Hepatology International (Zhang Y et al., 2009): A systematic meta-analysis of five randomized controlled trials enrolling 653 patients with chronic hepatitis B, evaluating thymalfasin 1.6 mg SC twice weekly versus no active treatment.

dose: 1.6 mg · frequency: twice weekly

Biomarker and Dosing Optimization # There are no validated biomarkers to predict which patients will respond to Ta1 therapy, and the standard dosing regimen (1.6 mg twice weekly) has not been systematically optimized through dose-finding studies for many of its investigated indications.

dose: 1.6 mg · frequency: twice weekly

constitution 💉 Dosing Amount 1.6 mg Frequency Twice weekly (standard); daily during chemotherapy cycles (cancer adjuvant) Duration 6-12 months (hepatitis B);

dose: 1.6 mg · frequency: Twice weekly

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

Reported side effects of Thymosin Alpha-1 include injection site reactions.

Most reported side effects are mild and transient.

Consult the detailed side effects profile for full information.

Thymosin Alpha-1: Immune Modulator Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Thymosin Alpha-1 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Thymosin Alpha-1 Immune Support Anti-Inflammatory approved Thymosin Alpha-1 Also known as: Thymalfasin, Zadaxin, Thymosin α1 Compare with 2 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated January 29, 2026 Citations Verified TL;DR Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland, approved in over 35 countries for treatment of hepatitis B, hepatitis C, and as an immune adjuvant.

Browse all immune peptides → Table of Contents 📌 TL;DR • Approved for hepatitis B treatment in multiple countries • Enhances T-cell mediated immunity • Stimulates dendritic cell maturation • Investigated as vaccine adjuvant Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Immune modulation for chronic hepatitis B, cancer adjuvant immunotherapy, and immune re

This bidirectional modulation may underlie its favorable safety profile, with minimal risk of cytokine storm or autoimmune activation reported in clinical use.

Importantly, Ta1 therapy in hepatitis B has demonstrated a favorable safety profile essentially equivalent to placebo, with no dose-limiting toxicities and no flu-like symptoms characteristic of interferon therapy.

rveillance # While the available safety data is reassuring, with no significant drug-related adverse events identified across clinical trials, large-scale post-marketing pharmacovigilance data from approved markets has not been comprehensively reviewed in the peer-reviewed literature.

sponse significantly higher with Ta1 versus control (RR 1.56) Response rates continued to improve for 6-12 months after treatment cessation Safety profile equivalent to placebo with no treatment discontinuations due to adverse events Effects of Thymosin Alpha-1 on Immune Function in Patients with Severe Sepsis (ETASS Study) , published in Critical Care (Wu J et al., 2013;

Combination therapy achieved 40% sustained response rate versus 20% with interferon monotherapy No additional adverse effects from Ta1 when combined with interferon Response rates continued to improve at follow-up beyond treatment cessation Randomized Controlled Trial of Thymosin Alpha-1 Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma , published in Hepatology (Gish RG et al., 2009): A randomized controlled trial investigating thymalfasin as adjuvant therapy combined with transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma.

ression Related Reading # Thymosin Alpha-1 research studies and evidence Thymosin Alpha-1 dosing protocols Thymosin Alpha-1 side effects profile Glutathione research guide LL-37 research guide Stay current on Thymosin Alpha-1 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

What are the side effects of Thymosin Alpha-1?

Unlike many synthetic peptides that remain in preclinical investigation, Ta1 has an extensive clinical track record spanning several decades, with over 4,400 patients studied in controlled clinical trials and widespread clinical use in approved markets.

Long-term effects of prolonged immune modulation, particularly in the context of cancer immunotherapy or chronic infection, warrant continued monitoring.

Combination therapy achieved 40% sustained response rate versus 20% with interferon monotherapy No additional adverse effects from Ta1 when combined with interferon Response rates continued to improve at follow-up beyond treatment cessation Randomized Controlled Trial of Thymosin Alpha-1 Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma , published in Hepatology (Gish RG et al., 2009): A randomized controlled trial investigating thymalfasin as adjuvant therapy combined with transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma.

While the advent of direct-acting antiviral agents (DAAs) has transformed hepatitis C treatment, Ta1 remains relevant in clinical settings where DAA access is limited or where patients have contraindications to standard therapies.

Baseline humoral immunity HBV DNA and HBeAg When: 3 months (hepatitis B indication) Why: Assess virological response; seroconversion may be delayed 💡 Key Considerations → No preservative in reconstituted solution - use immediately → Contraindication: Avoid in patients on immunosuppressive therapy for organ transplantation; caution in autoimmune diseases where immune stimulation could exacerbate condition Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Do not use if the reconstituted solution appears discolored or contains particulate matter. ⚗️ Suggested Bloodwork ( 6 tests) CBC with differential When: Baseline Why: Baseline immune cell counts Lymphocyte subset panel (CD4, CD8, NK cells) When: Baseline Why: Ta1 targets T-cell and NK cell function Hepatitis B panel (HBV DNA, HBeAg, HBsAg) When: Baseline Why: Required for hepatitis B indication; baseline viral status CMP with liver enzymes When: Baseline Why: Liver function baseline Immunoglobulin levels When: Baseline Why:

Restore access No thanks, continue reading Related Reading Peptide KPV anti-inflammatory tripeptide Peptide BPC-157 body protection compound Peptide Glutathione peptide How Thymosin Alpha-1 works at the cellular level Overview of Thymosin Alpha-1 benefits and applications Scientific Details Molecular Formula C129H215N33O55 Molecular Weight 3108.3 Da CAS Number 62304-98-7 Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn What is Thymosin Alpha-1? # Thymosin Alpha-1 (Ta1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein and colleagues in the 1970s.

Restore access No thanks, continue reading Related Reading Peptide KPV anti-inflammatory tripeptide Peptide BPC-157 body protection compound Peptide Glutathione peptide How Thymosin Alpha-1 works at the cellular level Overview of Thymosin Alpha-1 benefits and applications Scientific Details Molecular Formula C129H215N33O55 Molecular Weight 3108.3 Da CAS Number 62304-98-7 Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn What is Thymosin Alpha-1? # Thymosin Alpha-1 (Ta1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein and colleagues in the 1970s.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 14 min read Peptide Stacking Guide 2026: Best Combinations by Goal The definitive 2026 guide to peptide stacking organized by go

Peptide Protocol Wiki March 7, 2026 BPC-157 TB-500 AOD-9604 + 11 more Guide 14 min read Best Peptides for Menopause Symptoms: 2026 Research Guide Research guide covering peptides studied for menopause symptoms including hot flashes, bone loss, cognitive changes, skin aging, sleep disruption, and hormonal regulation.

Peptide Protocol Wiki February 17, 2026 Semaglutide Tirzepatide BPC-157 + 1 more You Might Also Like Related content you may find interesting Peptide Immune LL-37 Peptide Immune Thymalin Peptide Immune Glutathione Peptide Immune KPV Table of Contents What is Thymosin Alpha-1?

Peptide Protocol Wiki February 17, 2026 Semaglutide Tirzepatide BPC-157 + 1 more You Might Also Like Related content you may find interesting Peptide Immune LL-37 Peptide Immune Thymalin Peptide Immune Glutathione Peptide Immune KPV Table of Contents What is Thymosin Alpha-1?

Peptide Protocol Wiki February 17, 2026 Semaglutide Tirzepatide BPC-157 + 1 more You Might Also Like Related content you may find interesting Peptide Immune LL-37 Peptide Immune Thymalin Peptide Immune Glutathione Peptide Immune KPV Table of Contents What is Thymosin Alpha-1?

Restore access No thanks, continue reading Related Reading Peptide KPV anti-inflammatory tripeptide Peptide BPC-157 body protection compound Peptide Glutathione peptide How Thymosin Alpha-1 works at the cellular level Overview of Thymosin Alpha-1 benefits and applications Scientific Details Molecular Formula C129H215N33O55 Molecular Weight 3108.3 Da CAS Number 62304-98-7 Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn What is Thymosin Alpha-1? # Thymosin Alpha-1 (Ta1) is a naturally occurring 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein and colleagues in the 1970s.